首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Journal Of Cardiovascular Pharmacology

Journal Of Cardiovascular Pharmacology杂志,由Lippincott Williams and Wilkins Ltd.出版,于1979年创刊,Monthly,出版语言English,ISSN:0160-2446,E-ISSN:1533-4023。

投稿咨询
Journal Of Cardiovascular Pharmacology
Journal Of Cardiovascular Pharmacology
Journal Of Cardiovascular Pharmacology
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
4区
影响因子
2.5
CiteScore
4.6
期刊收录
SCI、SCIE

Journal Of Cardiovascular Pharmacology(中文译名:《心血管药理学杂志》),ISSN:0160-2446,EISSN:1533-4023,是Lippincott Williams and Wilkins Ltd.出版的国际性学术期刊,创刊于1979年,以Monthly形式稳定发行,2026年总发文量约101篇。该刊采用非OA开放访问,学科归属为医学 - 心血管系统。该刊是医学、心脏和心血管系统领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达2.5,2025年期刊CiteScore为4.6,2025年期刊自引率约4%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Journal Of Cardiovascular Pharmacology长期聚焦医学、心脏和心血管系统及相关产业的技术应用前沿,平均审稿周期约1月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、心脏和心血管系统领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,CHINA MAINLANDUSA、Italy、Japan、GERMANY (FED REP GER)、Brazil、France等为核心发文国家与地区;VIRGINIA COMMONWEALTH UNIVERSITYHARVARD UNIVERSITY、UNIVERSITY OF MISSISSIPPI、UNIVERSITY OF MISSISSIPPI MEDICAL CENTER、BRIGHAM & WOMEN'S HOSPITAL、CENTRAL SOUTH UNIVERSITY、FUDAN UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统 PHARMACOLOGY & PHARMACY 药学
4区 4区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统 PHARMACOLOGY & PHARMACY 药学
4区 4区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统 PHARMACOLOGY & PHARMACY 药学
4区 4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:CARDIAC & CARDIOVASCULAR SYSTEMS SCIE Q2 111 / 237

53.4

学科:PHARMACOLOGY & PHARMACY SCIE Q3 205 / 356

42.6

学科:CARDIAC & CARDIOVASCULAR SYSTEMS SCIE Q3 120 / 237

49.58

学科:PHARMACOLOGY & PHARMACY SCIE Q3 211 / 356

40.87

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:CARDIAC & CARDIOVASCULAR SYSTEMS SCIE Q2 111 / 231

52.2

学科:PHARMACOLOGY & PHARMACY SCIE Q3 209 / 352

40.8

学科:CARDIAC & CARDIOVASCULAR SYSTEMS SCIE Q3 119 / 231

48.7

学科:PHARMACOLOGY & PHARMACY SCIE Q3 207 / 353

41.5


中国学者近期发文

1
Integrating Network Pharmacology and In Vitro 3D Cardiac Organoid Model Validation to Investigate the Action Mechanism of Shenfu Xiangshao Decoction on Heart Failur

Author:Yao, Sijie; Zhang, Hui; Li, Min; Han, Shuo; Ding, Xinyue; Zhao, Xuan; Dai, Ting; Yang, Jin; Wang, Daying; Xing, Lina; Gao, Junqing; Zhu, Yanan; Liu, Zongjun

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2026; Vol. 87, Issue 4, pp. 283-298. DOI: 10.1097/FJC.0000000000001802

2
Role of the Gut Microbiome in Modulating Interactions Between β-Lactam Antibiotics and Statins in Coronary Heart Diseas

Author:Wang, Guohui; Luo, Yan; Song, Sangcang; Li, Xingde; Pan, Yaping; Zhao, Zhongwen; Wang, Bo; Yang, Qiongxiang; Yang, Feng; Fang, Tiantian

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2026; Vol. 87, Issue 4, pp. 299-309. DOI: 10.1097/FJC.0000000000001805

3
Therapeutic Effects of PCSK9 Inhibitors on Lp(a)-Associated Atherosclerosis: Evidence and Perspective

Author:Li, Xinyan; Wang, Zhongsu; Liang, Juan; Li, Bingsong; Meng, Qingxin; Gao, Mei

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2026; Vol. 87, Issue 4, pp. 229-241. DOI: 10.1097/FJC.0000000000001794

4
Lipid-Lowering Efficacy and Adverse Events of CETP Inhibitor Combination Therapy: A Systematic Review and Network Meta-Analysi

Author:Guo, Ping; Yu, Xinlin; Wei, Xinxin; Xiong, Xinlin; Jiang, Jie

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2026; Vol. 87, Issue 4, pp. 246-256. DOI: 10.1097/FJC.0000000000001785

5
Musculoskeletal Adverse Events Associated With Bempedoic Acid: A Real-World Pharmacovigilance Stud

Author:He, Yeqian; Wei, Yuqing; Jiang, Xia; Lu, Jiejiu

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2026; Vol. 87, Issue 3, pp. 192-200. DOI: 10.1097/FJC.0000000000001792

6
Lactylation-Related Gene Signature and Immune Infiltration Crosstalk in Heart Failure: Insights From Bulk and Single-Cell Transcriptomic

Author:Xie, Yao; Huang, Tieqiu; Wang, He; Yang, Jinhua; Zhou, Suzhen

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2026; Vol. 87, Issue 2, pp. 87-104. DOI: 10.1097/FJC.0000000000001775

7
Muscle Adverse Events Associated With Inclisiran: Data Mining of FAERS Database and Mendelian Randomization Analysi

Author:Liu, Dan; Liu, JiFang; Mao, Wei; Li, Xingxing; Hu, Bin; Zhang, Lin; Hu, Jing

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2026; Vol. 87, Issue 2, pp. 114-126. DOI: 10.1097/FJC.0000000000001778

8
Cardioprotective Effects of Soluble Guanylate Cyclase and Its α1 Subunit on Myocardial Ischemia/Reperfusion Injury via the PGC-1α/UCP2 Pathwa

Author:Li, Jiao; Li, Xinhang; Chen, Yafang; Fang, Linlin; Li, Qi; Wu, Hao; Liu, Yue; Qi, Xin; Wei, Liping

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2026; Vol. 87, Issue 1, pp. 40-50. DOI: 10.1097/FJC.0000000000001765

9
Retraction: LC3B, a Protein That Serves as an Autophagic Marker, Modulates Angiotensin II-induced Myocardial Hypertroph

Author:Huang, Jionghua; Pan, Wei; Ou, Dejin; Dai, Wenjun; Lin, Yuhui; Chen, Yongquan; Chen, Ximing

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2026; Vol. 87, Issue 1, pp. 62-62. DOI: 10.1097/FJC.0000000000001777

10
Traditional Chinese Medicine in the Treatment of Diabetic Cardiomyopathy: A Comprehensive Revie

Author:He, Jia-Xin; Xiao, Hai-Tao; Du, Meng-Meng; Hu, Min; Zheng, Zu-Guo

Journal: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2026; Vol. 87, Issue 1, pp. 7-18. DOI: 10.1097/FJC.0000000000001772


在线咨询

Journal Of Cardiovascular Pharmacology

国际简称:J CARDIOVASC PHARM参考译名:心血管药理学杂志

年发文量:101 CiteScore:4.6 是否预警:否 Gold OA文章占比:15.89% 研究类文章占比:70.30%

杂志社联系方式:LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621

Journal Of Cardiovascular Pharmacology